Guo Qian, Wang Tianwei, Huang Yusen, Wang Fangruyue, Hao Pingping, Fang Le
Department of Neurology, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130000, China.
Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun, 130000, China.
Neurol Sci. 2024 Aug;45(8):3563-3571. doi: 10.1007/s10072-024-07578-6. Epub 2024 May 9.
There is insufficient data on severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) infection in Chinese patients with multiple sclerosis (pwMS). This study aims to explore the manifestation of pwMS during the Coronavirus disease 2019 (COVID-19) pandemic and the effect of SARS-CoV-2 infection on the prognosis of MS in northern China.
In this cross-sectional study, an online self-administered questionnaire and telephone interviews were conducted among pwMS of northern China. Clinical correlation of SARS-CoV-2 infection since the onset of the COVID-19 pandemic in northern China was analyzed.
164 patients with an average age of 38.9 ± 12.2 years were included, of which 57.3% had a disease course ≤ 5 years. 33.5% of the patients were COVID-19 vaccinated. 87.2% received disease-modifying therapy (DMT), and the average immunotherapy duration was 1.9 ± 1.6 years. 83.5% were SARS-CoV-2 infected, 14.6% reported worsening of their original condition after infection, and 5.1% had a relapse of MS. Shorter disease course was independently related to infection risk (P = 0.046), whereas increasing age was related to aggravated behavioral symptoms (P = 0.008). However, gender, vaccination, and DMT were not associated with susceptibility or poor prognosis.
A shorter disease course is independently associated with an increased risk of SARS-CoV-2 infection, and age is associated with worsening disability. It seems to be safe and necessary to use DMT during the pandemic, however, the use of B cell-depletion agents should be approached with caution.
关于中国多发性硬化症患者（pwMS）感染严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的数据不足。本研究旨在探讨2019冠状病毒病（COVID-19）大流行期间pwMS的表现以及SARS-CoV-2感染对中国北方MS预后的影响。
在这项横断面研究中，对中国北方的pwMS患者进行了在线自填问卷和电话访谈。分析了自中国北方COVID-19大流行开始以来SARS-CoV-2感染的临床相关性。
纳入164例患者，平均年龄38.9±12.2岁，其中57.3%病程≤5年。33.5%的患者接种了COVID-19疫苗。87.2%接受了疾病修正治疗（DMT），平均免疫治疗时间为1.9±1.6年。83.5%的患者感染了SARS-CoV-2，14.6%的患者报告感染后原有病情恶化，5.1%的患者出现MS复发。较短的病程与感染风险独立相关（P=0.046），而年龄增长与行为症状加重相关（P=0.008）。然而，性别、疫苗接种和DMT与易感性或不良预后无关。
较短的病程与SARS-CoV-2感染风险增加独立相关，年龄与残疾恶化相关。在大流行期间使用DMT似乎是安全且必要的，然而，使用B细胞耗竭剂应谨慎。
